4.5 Review

Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects

期刊

NEUROCHEMISTRY INTERNATIONAL
卷 152, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuint.2021.105250

关键词

Agitation; Blood-based biomarkers; Neuropsychiatric symptoms; Inflammation

向作者/读者索取更多资源

Agitation is a common symptom in Alzheimer's disease (AD), and its treatment is urgently needed. Recent research on blood-based biomarkers of agitation in AD has provided new insights into its mechanisms and potential treatments. Inflammatory biomarkers are increased in patients with agitation and may predict the development and severity of agitation. Other biomarkers associated with agitation include markers of oxidative stress, brain cholesterol metabolism, and motor activity. These biomarkers have the potential to predict and monitor treatment response in interventional studies for agitation.
Agitation is a common neuropsychiatric symptom that becomes more prevalent as Alzheimer's disease (AD) increases in severity. The treatment of agitation is an urgent and unmet need due to the poor outcomes associated with it, its disruptive impact on patients and caregivers, and the lack of efficacious and safe treatments. Recent research on agitation in AD with blood-based biomarkers has advanced the search for its biomarkers beyond the brain and provides new insights to understand its mechanisms and improve treatments. Here, we reviewed studies of blood-based biomarkers of agitation in AD, which show that inflammatory biomarkers are increased in patients with agitation, may predict the development of agitation, and are associated with symptom severity. In addition, they may also track symptom severity and response to treatment. Other biomarkers associated with agitation include markers of oxidative stress, brain cholesterol metabolism, motor activity, and clusterin, a chaperone protein. These results are promising and need to be replicated. Preliminary evidence suggests a role for these biomarkers in interventional studies for agitation to predict and monitor treatment response, which may eventually help enrich study samples and deliver therapy likely to benefit individual patients. Advances in blood-based biomarkers of AD including those identified in -omic studies and high sensitivity assays provide opportunities to identify new biomarkers of agitation. Future studies of agitation and its treatment should investigate blood-based biomarkers to yield novel insights into the neurobiological mechanisms of agitation, monitoring symptoms and response to treatment, and to identify patients likely to respond to treatments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据